VIDEO: Take homes in DLBCL from ASCO 2023

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

One of the themes at ASCO that really echoes what we've been learning over the last year or 2 is the ongoing emergence of T-cell-engaging therapy as a mainstay of treatment for patients with relapsed or refractory large cell lymphoma. And we continue to get updates on molecules that are now FDA approved or in ongoing development, such as the bispecific antibodies, and better characterizing their activity and safety in the treatment of patients with relapsed or refractory large cell lymphoma.

This is work that is very promising and, as we see, there's an ongoing proliferation of trials evaluating these molecules, either as monotherapy or increasingly as part of combination-based treatment approaches in earlier lines of therapy in an attempt to leverage the activity and safety of the bispecific antibodies to improve outcomes for patients with relapsed or refractory, or even potentially newly diagnosed diffuse large b-cell lymphoma.